Supplementary Material for:

Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation

Welbeck Danquah, Catherine Meyer-Schwesinger, Björn Rissiek, Carolina Pinto, Arnau Serracant-Prat, Miriam Amadi, Domenica Iacenda, Jan-Hendrik Knop, Anna Hammel, Philine Bergmann, Nicole Schwarz, Joana Assunção, Wendy Rotthier, Friedrich Haag, Eva Tolosa, Peter Bannas, Eric Boué-Grabot, Tim Magnus, Toon Laeremans, Catelijne Stortelers, Friedrich Koch-Nolte*

*Corresponding author. Email: nolte{at}uke.de

Published 23 November 2016, Sci. Transl. Med. 8, 366ra162 (2016)
DOI: 10.1126/scitranslmed.aaf8463

This PDF file includes:

• Materials and Methods
• Fig. S1. Screening nanobodies for specific binding to P2X7.
• Fig. S2. Pharmacological characterization of nanobodies 13A7 and 14D5.
• Fig. S3. Bivalent nanobodies block (13A7) or potentiate (14D5) ATP-induced activation of P2X7 in primary mouse macrophages.
• Fig. S4. Bivalent nanobodies block (13A7) or potentiate (14D5) nucleotide-induced activation of P2X7 in primary mouse T cells.
• Fig. S5. Systemic injection of half-life–extended nanobodies ameliorates (13A7-HLE) or enhances (14D5-HLE) nephritis induced by antipodocyte antibodies.
• Table S1. Anti-mouse P2X7 nanobodies selected from llamas immunized with P2X7-transfected HEK cells or with a P2X7 cDNA expression vector.
• References (48–50)

[Download PDF]